COVID-19, resulting from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)infection, is an unprecedented public health emergency which has directly caused hundreds of thousandsof deaths around the world and put health systems under immense pressure and stretched them beyondtheir capacity. In recent months, massive immunization with newly developed COVID-19 vaccines hasshown promising results towards curbing the spread of COVID-19. However, variants identified indifferent regions have sparked concerns about a potentially diminished vaccine efficacy against thesevariants.Through collaboration with a consortium of academic advisers and our internal scientific intelligence,we have been monitoring the emergence of different SARS-Cov-2 variants worldwide. Consequently,we have generated a library of constructs encoding spike proteins of SARS-CoV-2 carrying definedmutations of projected biological significance, including but not limited to: the UK strain (B.1.1.7),South Africa strain (B.1.351), Brazil strain (P.1) and California strain (Cal.20C). These mutants havebeen further subcloned into expression vectors for two versions of the SRAS-CoV-2 spike protein:• Full-length pre-fusion SARS-CoV-2 spike glycoprotein (S-2P)• RBD-Fc fusion protein of SARS-CoV-2 spike glycoproteinIn addition, our engineered expression vectors contain a variety of tags, facilitating the production oftagged recombinant proteins for research and product development.During the current Stage II of the COVID-19 pandemic during which vaccines have shown promisingresults in containment of the virus spread, we anticipate our COVID-19 Spike Variants Panel willgreatly accelerate research and development in the following areas:• For the characterization of immune reactivities of sera from vaccinated individuals againstvariants;• To be used as probes for isolating and cloning of variant-specific human monoclonal antibodiesfrom infected individuals for development of new therapeutic antibodies;• To be used to generate immune profiles to stratify populations that may require additionalvaccination with variant-specific vaccines;• To be used for the development of surrogate in vitro neutralizing assays based on RBD-ACE2binding;• To further facilitate our understanding between the SARS-CoV-2 spike protein structure andantibody response, for the development of future vaccines with a broader-spectrum of antibodyresponse.At Immune Tech, it is our mission to engage our full capacity, knowledge base, and enthusiasm in oureffort to help combat the novel coronavirus pandemic. We look forward to your comments, suggestions,and collaboration.

 

COVID-19 Spike Variants Panel

 

 

 

 

 

 

 

Lineage Variants Name Location First Identified Key Mutation in Spike Catalog # Description Expression System Product Status
N/A WT Wuhan, China IT-002-032p Recombinant Spike Protein of COVID-19 Coronavirus (SARS-CoV-2/Wuhan/2019),                    Trimeric, His-tagged HEK293 Available
IT-002-031p Recombinant Spike Protein RBD Domain of COVID-19 Coronavirus (SARS-CoV-2/Wuhan2019),         Fc-His-tagged HEK293 Available
IT-002-036p Recombinant Spike Protein RBD Domain of COVID-19 Coronavirus (SARS-CoV-2/Wuhan2019),         His-tagged HEK293 Available
IT-002-038p Recombinant Spike Protein NTD Domain of COVID-19 Coronavirus (SARS-CoV-2/Wuhan2019),          Fc-His-tagged HEK293 Available
IT-002-039p Recombinant Spike Protein NTD Domain of COVID-19 Coronavirus (SARS-CoV-2/Wuhan2019),        His-tagged HEK293 Available
IT-002-030p Recombinant Spike  Protein S1 Region of COVID-19 Coronavirus (SARS-CoV-2/Wuhan2019),          His-tagged HEK293 Available
IT-002-034p Recombinant Spike  Protein S2 Region of COVID-19 Coronavirus (SARS-CoV-2/Wuhan2019), Trimeric, His-tagged HEK293 Available
B.1.1.7 Alpha Variant United Kingdom N501Y IT-002-032p-UK Recombinant Spike Protein of COVID-19 Coronavirus (SARS-CoV-2/UK/2020),  Trimeric, His-Tagged
mutations: 69-70del,  144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
HEK293 Available
N501Y IT-002-031p-UK Recombinant Spike Protein RBD Domain of COVID-19 Coronavirus (SARS-CoV-2/UK/2020),              Fc-His-tagged HEK293 Available
B.1.351 Beta Variant
 South Africa N501Y, E484K, K417N IT-002-032p-SA Recombinant Spike Protein of COVID-19 Coronavirus (SARS-CoV-2/SA/2020),                           Trimeric, His-Tagged HEK293 Available
N501Y, E484K, K417N IT-002-031p-SA Recombinant Spike Protein RBD Domain of COVID-19 Coronavirus (SARS-CoV-2/SA/2020),             Fc-His-tagged HEK293 Available
P.1 Gamma Variant Brazil N501Y, E484K, K417T IT-002-032p-BR Recombinant Spike Protein of COVID-19 Coronavirus (SARS-CoV-2/BR/2020),                         Trimeric, His-Tagged HEK293 Available
N501Y, E484K, K417T IT-002-031p-BR Recombinant Spike Protein RBD Domain of COVID-19 Coronavirus (SARS-CoV-2/BR/2020),             Fc-His-tagged HEK293 Available
B.1.427/B.1.429  Cal.20C California, USA L452R IT-002-032p-CA Recombinant Spike Protein of COVID-19 Coronavirus (SARS-CoV-2/CA/2020),                         Trimeric, His-Tagged HEK293 Available
L452R IT-002-031p-CA Recombinant Spike Protein RBD Domain of COVID-19 Coronavirus (SARS-CoV-2/CA/2020),             Fc-His-tagged HEK293 Avaialable
B.1.207 Nigeria P681H 002-032p-NG Recombinant Spike Protein of COVID-19 Coronavirus (SARS-CoV-2/NG/2020),                           Trimeric, His-Tagged HEK293 Coming Soon
B.1 EU1 Europe D614G IT-002-040p  Recombinant Spike Protein (D614G) of COVID-19 Coronavirus (SARS-CoV-2/Wuhan/2019),    Trimeric, His-tagged HEK293 Available
B.1 EU2 Europe D614G, A222V IT-002-032VGp Recombinant Spike Protein (A222V+D614G) of COVID-19 Coronavirus (SARS-CoV-2/Wuhan/2019), Trimeric, His-tagged HEK293 Available
B.1.617  Indian E154K, L452R, E484Q, D614G, P681R, Q1071H IT-002-032p-IN2
Recombinant Spike Protein (SARS-CoV-2/ Lineage B.1.617 mutant), Trimeric
HEK293 Available
B.1.617  Indian L452R, E484Q IT-002-031p-IN2 Spike RBD (CoVID-19/ Lineage B.1.617 mutant) HEK293 Available
New York  L5F, T95I, D253G, S477N, D614G, and A701V) IT-002-032p-NY
Recombinant Spike Protein (SARS-CoV-2/New York mutant), Trimeric
HEK293 Available
B.1.617.2  Delta Variant T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950N IT-002-032p-Delta Recombinant SARS-CoV-2 Spike Protein Delta mutant, Trimeric HEK293 Available
B.1.617.2  Delta Variant L452R, T478K IT-002-031p-Delta Spike RBD (CoVID-19/Delta variant) HEK293 Available
B.1.617.2  Delta Plus Variant T19R, T95I, G142D, E156G, F157del, R158del, W258L, K417N, L452R, T478K, D614G, P681R, D950N IT-002-032p-DeltaPlus Recombinant SARS-CoV-2 Spike Protein Delta Plus mutant, Trimeric HEK293 Available
B.1.617.2  Delta Plus Variant K417N, L452R, T478K IT-002-031p-DeltaPlus Spike RBD (CoVID-19/Delta Plus variant) HEK293 Available
C.37 Lambda Variant G75V, T76I,∆RSYLTPG246-252,D253N,L452Q,F490S,D614G,T859N IT-002-032p-Lambda Recombinant SARS-CoV-2 Spike Protein Lambda mutant, Trimeric HEK293 Available
C.37 Lambda Variant L452Q,F490S IT-002-031p-Lambda Spike RBD (CoVID-19/Lambda variant) HEK293 Available
B.1.621  Mu Variant T95I,Y144T, Y145S,ins146N,R346K,E484K,N501Y,D614G,P681H,D950N IT-002-032p-Mu Recombinant SARS-CoV-2 Spike Protein Mu mutant, Trimeric HEK293 Available
B.1.1.529  Omicron Variant A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F IT-002-032p-Omicron Recombinant SARS-CoV-2 Spike Protein Omicron mutant, Trimeric HEK293 Available
B.1.1.529  Omicron Variant G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K IT-002-031p-Omicron Spike RBD (CoVID-19/Omicron variant) HEK293 Available
B.1.1.529  Omicron Variant G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K IT-002-036p-Omicron Spike RBD (CoVID-19/Omicron variant), His-tagged HEK293 Available
B.1.1.529  Omicron Variant A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE IT-002-039p-Omicron Spike NTD (CoVID-19/Omicron variant), His-tagged HEK293 Available
B.1.1.529.2  Omicron BA.2 Variant T19I, Δ24-26, A27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K IT-002-032p-OmicronBA.2 Recombinant Spike Protein (SARS-CoV-2/ Omicron BA.2), Trimeric HEK293 Available